Rituximab and Prednisone as First-Line Therapy in Treating Patients With Immune Thrombocytopenic Purpura

NCT00486421 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

COMPLETED

Status

22

Enrollment

OTHER

Sponsor class

Conditions

Nonneoplastic Condition

Interventions

BIOLOGICAL: Rituximab
DRUG: Prednisone

Sponsor

Mayo Clinic

Collaborators

[object Object]